Seattle biotech gets its "Groove" on; ProStrakan wins FDA OK; CRO expands global staff;

@FierceBiotech: Abbott inks $470M pact for Biotest's Ph2 RA antibody program. Story | Follow @FierceBiotech

@JohnCFierce: This Tesaro deal reminds me of the success Clovis has had in raising big $$$. Experience+clear strategy in cancer is appealing to investors. | Follow @JohnCFierce

> Unable to win a quick victory in its trademark infringement suit against the similarly-sounding Marina Biotech, Seattle-based Mirina has found a simple solution. It's changed its name to Groove Biopharma. Story

> ProStrakan Group has received FDA approval  for Rectiv (nitroglycerin) Ointment 0.4% for the treatment of moderate to severe pain associated with chronic anal fissures. ProStrakan release

> The CRO Octagon Research Solutions is adding 100 people to its worldwide staff. Story

> Lipid Therapeutics says that it has harvested a positive set of data from its Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis. Lipid Theraputics release

> For the past two years, toxicology testing on animals has not been permitted in Europe's cosmetics industry. So that has accelerated a search for a way to determine, in vitro, whether repeated exposure of cosmetics has toxic effects. The hunt for biomarkers that indicate repeated-dose toxicity is an important part of the new animal-test-free cosmetics industry. Article

> Mass spectrometry can help narrow down biomarker candidates. Report

> There is no cure for Alzheimer's, so for now victory against the disease is measured by how long its onset can be postponed. According to one researcher in Copenhagen, "delaying the onset of the disease by five years would halve all costs of Alzheimer's disease and delaying onset and progression by only one year would reduce the number of Alzheimer's cases by about 10 percent." The best way to delay its onset is to diagnose it as early as possible through use of biomarkers. And that's where a group called PredictAD comes into play. Report

Pharma News

@FiercePharma: Forest fights back against Icahn in filing. Article | Follow @FiercePharma

> With cladribine gone, Gilenya takes center stage. Story

> Abbott eyes Humira tweaks on way to No. 1. Report

> Greek debt pushes drugmakers to cut off supplies. Item

> AZ announces $1.8B dental-unit sale. Article

Drug Delivery News

> FDA looking for advice on regulating nanotech. Story

> Europe's Bydureon approval is victory for Alkermes. Report

> J&J drops Cypher drug-coated stents in more bad news for SurModics. Piece

> Body's blood-clotting machinery harnessed against cancer. Item

> Neural probe to include microchannels to deliver drugs to tinnitus sufferers. Article

> NIST to test the value of gold in drug-delivering nanoparticles. Article

Medical Device News

> Medtronic faces Senate scrutiny over Infuse. Article

> 3M accuses Porton CEO of blackmail. News

> GAO: FDA doesn't oversee device recalls properly. Article

> AZ, Dentsply reach deal on Astra Tech. Story

> Mauna Kea looks to raise $67.7M in IPO. Report

> Mendor raises $11.7M in Series B. Item

And Finally... This just in: Fear and other types of negative emotions can really help you remember something, according to researchers at Washington University. Story

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.